May 31, 2016
Recommended Topic Related To:

VPRIV

"The U.S. Food and Drug Administration today approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, a rare genetic disorder.

Gaucher disease occurs in people who do not produce e"...

A A A

VPRIV




PATIENT INFORMATION

  • Advise patients that VPRIV is a treatment that is given intravenously every other week. The infusion typically takes up to 60 minutes.
  • Advise patients that VPRIV may cause hypersensitivity reactions [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 5/21/2015
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.